Notably, the discovery that ~15% of all non-small cell lung cancers (NSCLC) demonstrate dependance on epidermal growth factor receptor (EGFR) signaling led to the generation of tyrosine kinase inhibitors (TKI) targeting EGFR signaling. Here, EGFR is linked to non-small cell lung carcinoma.